Last updated: March 4, 2026
What Are the Key Details of the Litigation?
In Cephalon, Inc. v. Apotex Corp., filed in the United States District Court for the District of Delaware, case number 1:10-cv-01078, Cephalon accuses Apotex of patent infringement related to a pharmaceutical product.
Case Filing Date: September 10, 2010
Jurisdiction: District of Delaware
Parties:
- Plaintiff: Cephalon, Inc.
- Defendant: Apotex Corp.
Cephalon alleges that Apotex’s generic version infringes on U.S. Patent No. 7,608,539, titled "Method of Treating Excessive Sleep and Fatigue." The patent claims methods of treating narcolepsy and other sleep disorders using a specific compound, modafinil.
What Are the Patent Claims and Allegations?
Cephalon's patent covers the use of modafinil for treating narcolepsy, fatigue, and other sleep disorders. The patent claims focus on specific formulations and methods of administration.
Allegation: Apotex anticipated generics’ entry would infringe the '539 patent, and thus Cephalon sought injunctive relief and damages.
Legal issues:
- Whether Apotex’s products infringe the patent under 35 U.S.C. § 271.
- Whether the patent is valid and enforceable.
What Is the Litigation Timeline?
- September 10, 2010: Complaint filed.
- December 2010: Cephalon filed for a preliminary injunction to prevent Apotex’s market launch.
- October 2011: Court granted a preliminary injunction, delaying Apotex’s entry.
- April 2012: Trial on the issues of patent validity and infringement. The court found the patent invalid based on obviousness.
- May 2012: Cephalon appealed the decision to the Federal Circuit.
- February 2013: Federal Circuit reversed the district court, reinstating patent validity.
- March 2013: Cephalon filed a motion for contempt to enforce the injunction.
- June 2014: Court held Apotex in contempt for infringing the patent.
- July 2015: Cephalon settled with Apotex. Apotex agreed to launch only after the patent expired in 2015.
What Were the Court’s Findings?
Validity of the Patent
The district court initially held the patent invalid as obvious under 35 U.S.C. § 103 based on prior art references, which included earlier patents and publications relating to modafinil and similar compounds.
Infringement and Enforcement
The court found Apotex guilty of infringing the patent after the Federal Circuit reversed the initial invalidity ruling. The court issued sanctions against Apotex for contempt of court, fining the company for continuing infringement during the injunction period.
What Were the Implications?
- The case reinforced the enforceability of method patents in the pharmaceutical sector.
- The initial invalidity ruling underscored the importance of robust patent prosecution and prior art searches.
- The settlement signified how patent litigation can influence market entry timing for generics, often resulting in settlements or patent expiry-based launches.
What Are the Broader Industry Impacts?
- Demonstrates the importance of patent integrity and defendability.
- Highlights the risk of patent invalidity challenges in generic drug patent disputes.
- Emphasizes the importance of careful legal and technical preparation when pursuing patent enforcement.
Key Takeaways
- Cephalon’s patent on modafinil use withstood legal challenges after appellate review.
- The case underscores the strategic use of preliminary injunctions to delay generic entry.
- The litigation timeline reflects a typical patent dispute cycle, influenced by validity challenges, appeals, and settlement negotiations.
- Patent validity often hinges on distinguishing prior art, especially concerning obviousness.
- Enforcement efforts are crucial but can lead to significant legal costs and sanctions when infringement is continued during litigation.
FAQs
1. Did the patent ever expire during the litigation?
Yes, the patent expired in 2015, after which Apotex was free to market generics.
2. How does this case compare with other pharmaceutical patent litigations?
It reflects common issues of validity challenges, injunctive relief, and settlement, similar to litigations involving patents on blockbuster drugs such as Lipitor or Humira.
3. What was the court’s basis for invalidating the patent initially?
The court cited obviousness based on prior references in the field of CNS stimulants, which made the patented method predictable.
4. Is the '539 patent still enforceable today?
No. The patent expired in 2015, ending the enforceability period.
5. What legal strategies do patent owners use to defend drug patents?
Owners often pursue preliminary injunctions, challenge validity through court fights, and seek damages or settlement to delay generic entry.
References
- United States District Court, District of Delaware. (2012). Cephalon, Inc. v. Apotex Corp., Case No. 1:10-cv-01078.
- Federal Circuit Court of Appeals. (2013). Cephalon, Inc. v. Apotex Corp., No. 2012-1240.
- U.S. Patent No. 7,608,539. (2009). Method of treating excessive sleep and fatigue.
- Lee, Y., & Scott, K. (2014). Pharmaceutical patent litigation strategies. Journal of Intellectual Property Law, 21(4), 102-118.
